Cingulate Inc. Capital Expenditures
Cingulate Inc. (CING) reported Capital Expenditures of $128.26 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13
- Cingulate Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $67.08K.
- Cingulate Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $61.18K.
- Cingulate Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $156.21K, a 21.29% decline year-over-year.
- Cingulate Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00.
- Cingulate Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $162.14K, a 23.45% decline from fiscal 2024.
- Cingulate Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $211.80K, a 5.49% decline from fiscal 2023.
- Cingulate Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $224.10K, a 46.07% increase from fiscal 2022.
- Cingulate Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $153.42K, a 81.17% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $128.26K 10-Q · filed 2026-08-13 | $284.48K derived: sum of 3 quarters · filed 2026-08-13 | $284.48K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $61.18K 10-Q · filed 2026-05-14 | $217.40K derived: sum of 2 quarters · filed 2026-05-14 | $217.40K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2025-12-31 | $156.21K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $156.21K derived: sum of 2 quarters · filed 2026-03-18 | $162.14K 10-K · filed 2026-03-18 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.92K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $5.92K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $198.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $57.67K derived: sum of 2 quarters · filed 2026-03-18 | $130.29K derived: sum of 3 quarters · filed 2026-03-18 | $211.80K 10-K · filed 2026-03-18 |
| 2024-09-30 | -$140.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$68.17K derived: sum of 2 quarters · filed 2025-11-13 | $13.34K 10-Q · filed 2025-11-13 | $200.30K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $72.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $154.13K 10-Q · filed 2025-08-19 | $341.09K derived: sum of 3 quarters · filed 2025-08-19 | $341.09K derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | $81.51K 10-Q · filed 2025-05-08 | $268.47K derived: sum of 2 quarters · filed 2025-05-08 | $268.47K derived: sum of 3 quarters · filed 2025-05-08 | $268.47K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $186.96K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $186.96K derived: sum of 2 quarters · filed 2025-03-27 | $186.96K derived: sum of 3 quarters · filed 2025-03-27 | $224.10K 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.00 derived: sum of 2 quarters · filed 2024-11-07 | $37.14K 10-Q · filed 2024-11-07 | $180.16K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $37.14K 10-Q · filed 2024-08-13 | $180.16K derived: sum of 3 quarters · filed 2024-08-13 | $180.16K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $37.13K 10-Q · filed 2024-05-08 | $180.16K derived: sum of 2 quarters · filed 2024-05-08 | $180.16K derived: sum of 3 quarters · filed 2024-05-08 | $180.16K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $143.02K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $143.02K derived: sum of 2 quarters · filed 2024-04-01 | $143.02K derived: sum of 3 quarters · filed 2024-04-01 | $153.42K 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $10.40K 10-Q · filed 2023-11-13 | $720.41K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $10.40K 10-Q · filed 2023-08-14 | $720.41K derived: sum of 3 quarters · filed 2023-08-14 | $736.18K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $10.40K 10-Q · filed 2023-05-10 | $720.41K derived: sum of 2 quarters · filed 2023-05-10 | $736.18K derived: sum of 3 quarters · filed 2023-05-10 | $758.67K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $710.01K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $725.78K derived: sum of 2 quarters · filed 2023-03-10 | $748.27K derived: sum of 3 quarters · filed 2023-03-10 | $814.74K 10-K · filed 2023-03-10 |
| 2021-09-30 | $15.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $38.26K derived: sum of 2 quarters · filed 2022-11-14 | $104.73K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $22.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $88.95K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $66.47K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $402.10K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |